Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.68
NAS:ALKS's Cash-to-Debt is ranked lower than
73% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:ALKS: 1.68 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.53 Max: No Debt
Current: 1.68
Equity-to-Asset 0.70
NAS:ALKS's Equity-to-Asset is ranked higher than
54% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ALKS: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALKS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.66 Max: 0.97
Current: 0.7
-0.15
0.97
Piotroski F-Score: 4
Altman Z-Score: 10.06
Beneish M-Score: -2.73
WACC vs ROIC
14.91%
-19.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -25.96
NAS:ALKS's Operating Margin % is ranked higher than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:ALKS: -25.96 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALKS' s Operating Margin % Range Over the Past 10 Years
Min: -35.7  Med: -18.36 Max: 41.29
Current: -25.96
-35.7
41.29
Net Margin % -25.61
NAS:ALKS's Net Margin % is ranked higher than
60% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:ALKS: -25.61 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALKS' s Net Margin % Range Over the Past 10 Years
Min: -36.15  Med: -13.55 Max: 69.37
Current: -25.61
-36.15
69.37
ROE % -16.27
NAS:ALKS's ROE % is ranked higher than
63% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:ALKS: -16.27 )
Ranked among companies with meaningful ROE % only.
NAS:ALKS' s ROE % Range Over the Past 10 Years
Min: -18.25  Med: -5.96 Max: 65.64
Current: -16.27
-18.25
65.64
ROA % -11.43
NAS:ALKS's ROA % is ranked higher than
66% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:ALKS: -11.43 )
Ranked among companies with meaningful ROA % only.
NAS:ALKS' s ROA % Range Over the Past 10 Years
Min: -12.04  Med: -4.55 Max: 27.26
Current: -11.43
-12.04
27.26
ROC (Joel Greenblatt) % -57.83
NAS:ALKS's ROC (Joel Greenblatt) % is ranked higher than
66% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:ALKS: -57.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.03  Med: -16.97 Max: 131.93
Current: -57.83
-61.03
131.93
3-Year Revenue Growth Rate 5.50
NAS:ALKS's 3-Year Revenue Growth Rate is ranked higher than
51% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:ALKS: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALKS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 9.9 Max: 69.6
Current: 5.5
-20.2
69.6
GuruFocus has detected 2 Warning Signs with Alkermes PLC $NAS:ALKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALKS's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ALKS Guru Trades in Q2 2016

PRIMECAP Management 2,505,450 sh (New)
Ken Fisher 123,094 sh (+2.33%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments 249,164 sh (-27.89%)
» More
Q3 2016

ALKS Guru Trades in Q3 2016

George Soros 4,600 sh (New)
PRIMECAP Management 3,153,560 sh (+25.87%)
Ken Fisher 129,607 sh (+5.29%)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Pioneer Investments 155,087 sh (-37.76%)
» More
Q4 2016

ALKS Guru Trades in Q4 2016

Steven Cohen 84,400 sh (New)
PRIMECAP Management 6,376,270 sh (+102.19%)
George Soros 7,200 sh (+56.52%)
Vanguard Health Care Fund 8,660,076 sh (+0.66%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Ken Fisher 118,407 sh (-8.64%)
Pioneer Investments 103,137 sh (-33.50%)
» More
Q1 2017

ALKS Guru Trades in Q1 2017

Joel Greenblatt 51,566 sh (New)
Jim Simons 124,886 sh (New)
Steven Cohen 250,200 sh (+196.45%)
PRIMECAP Management 7,856,543 sh (+23.22%)
Vanguard Health Care Fund 8,694,176 sh (+0.39%)
Murray Stahl 25,000 sh (unchged)
George Soros Sold Out
Pioneer Investments Sold Out
Jeff Auxier 26,651 sh (-0.37%)
Ken Fisher 110,407 sh (-6.76%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:JAZZ, NAS:SGEN, NAS:TSRO, NAS:ALNY, NAS:BIVV, NAS:EXEL, NAS:UTHR, NAS:IONS, OTCPK:GMXAY, OTCPK:NVZMF, NAS:NBIX, NAS:GLPG, NAS:TECH, NAS:KITE, NAS:ACAD, NAS:BLUE, OTCPK:BTGGF, NAS:CBPO, NAS:NKTR, NYSE:XON » details
Traded in other countries:8AK.Germany,
Headquarter Location:Ireland
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Alkermes is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Ratios

vs
industry
vs
history
Forward PE Ratio 1111.11
ALKS's Forward PE Ratio is ranked lower than
100% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. ALKS: 1111.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 7.25
ALKS's PB Ratio is ranked lower than
77% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ALKS: 7.25 )
Ranked among companies with meaningful PB Ratio only.
ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.66  Med: 4.25 Max: 12.73
Current: 7.25
1.66
12.73
PS Ratio 11.27
ALKS's PS Ratio is ranked higher than
52% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ALKS: 11.27 )
Ranked among companies with meaningful PS Ratio only.
ALKS' s PS Ratio Range Over the Past 10 Years
Min: 2.19  Med: 7.1 Max: 18.85
Current: 11.27
2.19
18.85
EV-to-EBIT -44.23
ALKS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ALKS: -44.23 )
Ranked among companies with meaningful EV-to-EBIT only.
ALKS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17501.7  Med: -22.5 Max: 436.6
Current: -44.23
-17501.7
436.6
EV-to-EBITDA -86.18
ALKS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ALKS: -86.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALKS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1362.6  Med: 5.4 Max: 262.1
Current: -86.18
-1362.6
262.1
Current Ratio 3.60
ALKS's Current Ratio is ranked lower than
53% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ALKS: 3.60 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.22 Max: 35.69
Current: 3.6
2.01
35.69
Quick Ratio 3.30
ALKS's Quick Ratio is ranked lower than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ALKS: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.99 Max: 35.69
Current: 3.3
1.95
35.69
Days Inventory 138.89
ALKS's Days Inventory is ranked lower than
53% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ALKS: 138.89 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 128.98 Max: 166.33
Current: 138.89
86.09
166.33
Days Sales Outstanding 82.51
ALKS's Days Sales Outstanding is ranked lower than
69% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ALKS: 82.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 93.54
Current: 82.51
27.46
93.54
Days Payable 142.92
ALKS's Days Payable is ranked higher than
72% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ALKS: 142.92 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 142.92
Current: 142.92
39.15
142.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ALKS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -10.2 Max: 2.1
Current: -4.5
-16.1
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 36.06
ALKS's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ALKS: 36.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.18  Med: 7.26 Max: 343
Current: 36.06
2.18
343
Price-to-Tangible-Book 10.76
ALKS's Price-to-Tangible-Book is ranked lower than
82% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ALKS: 10.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 7.69 Max: 365.22
Current: 10.76
1.24
365.22
Price-to-Intrinsic-Value-Projected-FCF 10.72
ALKS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
77% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. ALKS: 10.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALKS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2  Med: 4.04 Max: 20.95
Current: 10.72
2
20.95
Price-to-Median-PS-Value 1.58
ALKS's Price-to-Median-PS-Value is ranked lower than
79% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALKS: 1.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.57 Max: 14.41
Current: 1.58
0.38
14.41
Earnings Yield (Greenblatt) % -2.27
ALKS's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ALKS: -2.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.28  Med: 2.6 Max: 53.4
Current: -2.27
-2.28
53.4

More Statistics

Revenue (TTM) (Mil) $780.7
EPS (TTM) $ -1.31
Beta2.40
Short Percentage of Float8.84%
52-Week Range $39.65 - 62.50
Shares Outstanding (Mil)153.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 910 1,098 1,373
EPS ($) 0.05 0.65 1.71
EPS without NRI ($) 0.05 0.65 1.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALKS

Headlines

Articles On GuruFocus.com
Stocks That Are Beating the Market Apr 12 2017 
Drug Addiction Treatment Should Start in Emergency Room Apr 04 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 

More From Other Websites
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : May 26, 2017 May 26 2017
Why These Drug Stocks May Surge May 15 2017
Big Week Ahead for Alkermes May 15 2017
Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting May 11 2017
3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018 May 04 2017
[$$] Three Top Picks in Smaller Pharma May 02 2017
Blog Coverage Alkermes Announces Completion of Patient Enrolment in ALKS 3831 Study for the... May 02 2017
Biotechs Cruise On 6-Day Upswing Despite Price Target Cuts For This Duo May 01 2017
ETFs with exposure to Alkermes Plc : May 1, 2017 May 01 2017
Alkermes' Revenue Jumps 22% May 01 2017
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : May 1, 2017 May 01 2017
Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS... May 01 2017
Edited Transcript of ALKS earnings conference call or presentation 27-Apr-17 12:30pm GMT Apr 28 2017
Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Apr 28 2017
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss Apr 28 2017
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports Apr 27 2017
Alkermes reports 1Q loss Apr 27 2017
Biotech Earnings Roundup: Exact Sciences Flying Higher Apr 27 2017
Alkermes plc Reports First Quarter 2017 Financial Results Apr 27 2017
Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care... Apr 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)